Gilead Sciences has expanded six royalty-free licenses to cover investigational once-yearly lenacapavir for HIV prevention, starting manufacturing preparations before the pivotal PURPOSE 365 study has delivered its results.
Novo Nordisk has expanded its artificial-intelligence strategy through a collaboration with Anthropic that will test Claude Science in pharmaceutical R&D, adding another AI partner as the drugmaker seeks faster research productivity amid intensifying competitive pressure.
Siemens Healthineers has made the CN-3000 and CN-6000 hemostasis systems available for U.S. patient testing, targeting automation, laboratory consolidation and recurring assay revenue as its broader Diagnostics business battles weaker growth.
FDA clearance for Medtronic’s LigaSure RAS Maryland instrument adds a familiar vessel-sealing technology to Hugo, strengthening the company’s effort to build a broader robotic surgery ecosystem around instruments, procedures and recurring revenue.
Roche has secured FDA Priority Review for Enspryng in myelin oligodendrocyte glycoprotein antibody-associated disease after Phase 3 data showed a 68% reduction in relapse risk versus placebo.
Enhertu reduced the risk of progression or death by 37% against pembrolizumab plus chemotherapy in first-line HER2-mutant metastatic non-small cell lung cancer, potentially opening another earlier-treatment market for AstraZeneca and Daiichi Sankyo.
Johnson & Johnson’s Rybrevant combination produced a median overall survival of 34.3 months in first-line EGFR exon 20 insertion-positive lung cancer, although the protocol-specified comparison did not reach statistical significance after extensive crossover from chemotherapy.
Senseonics and Beta Bionics plan to integrate Eversense 365 with iLet, pairing one-year implantable CGM with automated insulin delivery.
FDA clears CurveBeam AI’s BoneVue CT bone-density technology, while a second HiRise clearance remains necessary for its planned BMD SaaS launch.
Beta Bionics wins FDA clearance for Mint, targets a Q1 2027 launch and prices a $150 million offering to support commercialization.